Lurasidone
 Above: molecular structure of lurasidone | |
| Clinical data | |
|---|---|
| Pronunciation | /ljʊəˈræsɪˌdoʊn/ |
| Trade names | Latuda, others |
| Synonyms | SM-13496 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611016 |
| License data |
|
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Atypical antipsychotic[2] |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 9–19% (oral)[3] |
| Protein binding | ~99%[9] |
| Metabolism | Liver (CYP3A4-mediated)[3] |
| Elimination half-life | 18–40 hours[3][9] |
| Excretion | Faecal (67–80%), renal (9–19%)[3][9] |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | |
| ECHA InfoCard | |
| Chemical and physical data | |
| Formula | C28H36N4O2S |
| Molar mass | 492.68 g·mol−1 |
| 3D model (JSmol) | |
| Specific rotation | [α]20D −59° |
| Melting point | 176 to 178 °C (349 to 352 °F) |
| Solubility in water | 0.224 |
Expression error: Unexpected < operator.Expression error: Unexpected < operator.Expression error: Unexpected < operator.
Lurasidone, sold under the brand name Latuda, is an atypical antipsychotic medication that is used to treat schizophrenia and bipolar depression. It is taken by mouth.
It was first approved for medical use in the United States in 2010.[2] In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as on its own (monotherapy) or adjunctively with lithium or valproate. It was first approved for medical use in the United States in 2010.[2] In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as on its own (monotherapy) or adjunctively (together) with lithium or valproate.
Lurasidone Media
ID-14283, the main active metabolite. The hydroxylation of the norbornane ring is highlighted. The other active metabolite, ID-14326, has the OH group in endo position.
The main inactivation step by oxidative N-dealkylation produces the metabolites ID-11614 and ID-20219.
Latuda 40mg and 80mg bottles with 80mg tablets.
_bottles.png)
References
- ↑ Lurasidone (Latuda) Use During Pregnancy. Drugs.com (5 February 2020). Retrieved 12 May 2020.
- ↑ 2.0 2.1 2.2 Lurasidone Hydrochloride Monograph for Professionals. Drugs.comAmerican Society of Health-System Pharmacists. Retrieved 21 March 2019.
- ↑ 3.0 3.1 3.2 3.3 3.4 Product information Latuda (lurasidone hydrochloride). TGA eBusiness Services (28 October 2022)Therapeutic Goods Administration. Retrieved 28 October 2022.
- ↑ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA) (21 June 2022). Retrieved 10 April 2023.
- ↑ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial (in pt-BR) (31 March 2023)Diário Oficial da União. Retrieved 16 August 2023.
- ↑ Latuda EPAR. European Medicines Agency (EMA) (17 September 2018). Retrieved 12 May 2020.
This article incorporates text from this source, which is in the public domain.
- ↑ Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc) (16 January 2019). Retrieved 12 May 2020.
- ↑ Latuda- lurasidone hydrochloride tablet, film coated. DailyMed. Retrieved 12 May 2020.
- ↑ 9.0 9.1 9.2 Latuda: EPAR – Product Information (14 April 2016)European Medicines Agency. Retrieved 27 February 2017.